This video is featured in the 2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Summary: Breast Cancer Highlights - KEYNOTE-522, NATALEE, DESTINY-BREAST12, and CAPItello-290

514 views
September 23, 2024

Chapters

KEYNOTE-522: Immunotherapy in Early-Stage TNBC

00:00

Adjuvant Endocrine Therapy Advances

02:45

DESTINY-BREAST12: HER2-Low Breast Cancer Treatment

04:20

CAPItello-290: AKT Pathway Targeting

06:49

Comments 0
Login to view comments. Click here to Login